Investigating how certain proteins affect treatment resistance in brain cancer
Official title: STAT5/OLIG2 regulation of GBM therapeutic resistance and recurrence - Resubmit 3.22
Funded at Mayo Clinic Arizona · NIH-11017809 · Data updated 2026-11-12
This study is looking at how certain proteins in glioblastoma, a tough type of brain cancer, might make it harder for treatments to work, with the hope of finding new ways to help patients feel better and live longer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Arizona NIH-funded |
| Lab location | 1 site (Scottsdale, United States) |
| Project start | February 21, 2023 |
| Project end | January 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $595,640 |
| NIH project number | 5R01CA271431-03 |
| Project ID | NIH-11017809 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with glioblastoma who have tumors expressing the active form of the EGFR protein.
✕Less likely to help
Patients with glioblastoma who do not have the active form of EGFR or those with other types of brain tumors may not benefit from this research.
What this research studies
This research focuses on glioblastoma (GBM), a highly aggressive brain cancer, and aims to understand how specific proteins, particularly STAT5 and EGFR, contribute to the cancer's resistance to treatment. By examining the signaling pathways activated by these proteins, the research seeks to identify new therapeutic strategies that could improve patient outcomes. The study will analyze primary GBM samples to ensure that the findings are relevant to actual patient tumors, particularly those expressing the active form of EGFR. The goal is to uncover mechanisms that could lead to more effective treatments for patients suffering from this challenging disease.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that overcome resistance in glioblastoma patients, potentially improving survival rates.
How similar studies have gone: Previous research has shown that targeting signaling pathways in glioblastoma can lead to improved treatment outcomes, suggesting that this approach may also be promising.
Where this research is happening
-
Mayo Clinic Arizona
Scottsdale, United States Active
Researchers
- Principal investigator: Tran, Nhan L — Mayo Clinic Arizona
- Study coordinator: Tran, Nhan L
Related research
Other NIH-funded projects on the same topics.
-
Keloid recurrence study using multi-omics in diverse patients
A research effort will look at why keloids come back after surgery, especially in African American patients, using comprehensive molecular data from patient samples.
-
Combined Imaging and RNA Markers to Predict Head and Neck Cancer Recurrence
A research project aims to use imaging and RNA data to better predict if head and neck cancer will come back, helping doctors tailor treatments for patients.
-
Oral cancer recurrence predictor using tumor microbes and gene activity
This NIH grant explores how bacteria and immune signals inside oral cancer tumors relate to whether the cancer comes back, with the aim of making a practical risk predictor for patients.
-
How air pollution affects recurrent heart events in older adults
This grant explores how air pollution, especially PM2.5, influences the recurrence and progression of heart problems in people aged 65 and older.
-
Gene expression marks high risk for very late breast cancer return
A patient-focused study aims to find gene patterns that identify women with early breast cancer who are most likely to have cancer come back more than a decade later.
-
AI to predict melanoma coming back using tumor images, gene data, and pathology
This project is building an AI tool that uses detailed tumor pictures, gene activity, and pathology reports to help doctors predict whether early-stage (stage I or II) melanoma might return.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.